Reddy Uma M, Mennuti Michael T
Pregnancy and Perinatology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-7510, USA.
Obstet Gynecol. 2006 Jan;107(1):167-73. doi: 10.1097/01.AOG.0000194186.34664.a9.
The National Institute of Child Health and Human Development (NICHD), the Society for Maternal-Fetal Medicine, and the American College of Obstetricians and Gynecologists (ACOG), cosponsored a workshop on December 16-17, 2004, to discuss the evidence for first-trimester Down syndrome screening and to explore the effects of combining first- and second-trimester screening, given the results of recent U.S. trials. The experts evaluated the evidence for offering first-trimester screening to provide individual risk assessment for Down syndrome. First-trimester screening has been demonstrated to provide efficient Down syndrome risk assessment, with a detection rate of 84% (95% confidence interval 80-87%), which is clinically comparable to the second-trimester quadruple screen at a fixed false-positive rate of 5%. The participants at the workshop concluded that at this time there is sufficient evidence to support implementing first-trimester Down syndrome risk assessment in obstetric practice in the United States, provided that certain requirements can be met. These requirements include training and quality control standards for first-trimester nuchal translucency measurement and laboratory assays, access to chorionic villus sampling, and appropriate counseling regarding screening options.
美国国立儿童健康与人类发展研究所(NICHD)、母胎医学协会以及美国妇产科医师学会(ACOG)于2004年12月16日至17日共同主办了一次研讨会,以讨论孕早期唐氏综合征筛查的证据,并根据美国近期试验的结果探讨联合孕早期和孕中期筛查的效果。专家们评估了提供孕早期筛查以进行唐氏综合征个体风险评估的证据。孕早期筛查已被证明能提供有效的唐氏综合征风险评估,检出率为84%(95%置信区间80 - 87%),在固定假阳性率为5%时,其临床效果与孕中期四联筛查相当。研讨会上的参与者得出结论,目前有足够的证据支持在美国产科实践中实施孕早期唐氏综合征风险评估,前提是能够满足某些要求。这些要求包括孕早期颈部透明带测量和实验室检测的培训及质量控制标准、绒毛取样的途径以及关于筛查选项的适当咨询。